Antiretroviral-Sparing Concept: An Exploratory Phase II, Randomized, Single Blind Placebo-Controlled Study to Investigate the Effect of Therapeutic Immunization on the Quantity of HIV-Specific T Cell Precursors During Highly Active Antiretroviral Therapy Followed by Analytical Treatment Interruption.

Trial Profile

Antiretroviral-Sparing Concept: An Exploratory Phase II, Randomized, Single Blind Placebo-Controlled Study to Investigate the Effect of Therapeutic Immunization on the Quantity of HIV-Specific T Cell Precursors During Highly Active Antiretroviral Therapy Followed by Analytical Treatment Interruption.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2013

At a glance

  • Drugs LC 002 (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Sponsors Genetic Immunity
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 May 2012 Primary endpoint 'Proliferation-marker-levels' has been met, according to Genetic Immunity.
    • 15 Sep 2011 Primary endpoint identified as proliferation marker levels as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top